Brief: Sorrento Announces Covishield (Sti-9199) Antibody Nasal Drops Prevent Productive Sars-Cov-2 Infections When Given 24 Hours Prior To Virus Exposure
02/03/2022 16:39
Sorrento Therapeutics Inc SRNE.O :
* SORRENTO ANNOUNCES COVISHIELD (STI-9199) ANTIBODY NASAL
DROPS
PREVENT PRODUCTIVE SARS-COV-2 INFECTIONS WHEN GIVEN 24 HOURS
PRIOR TO VIRUS EXPOSURE
* SORRENTO THERAPEUTICS INC - IND FOR INTRANASAL STI-9199
(COVISHIELD) PRODUCT WAS CLEARED BY FDA TO PROCEED
Source text for Eikon: ID:nGNX7brbvz
Further company coverage: SRNE.O
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20